ProBioGen entered a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen’s DirectedLuck transposase technology. Financial terms of the agreement were not disclosed.
 
ProBioGen and Boehringer Ingelheim have collaborated going back to 2011, when the company was one of the early adopters of ProBioGen’s afucosylation technology GlymaxX. 
 
The new project further expands the partner’s long-term collaboration on new technologies for R&D. It contributes to Boehringer Ingelheim’s goal of using cutting-edge technologies across the whole biopharmaceutical value chain to help accelerate the development of novel treatments and transforming the lives of millions of humans and animals.

ProBioGen’s DirectedLuck transposase system combines an optimized highly active transposase and transposon with epigenetic targeting. It’s equipped with a recognition domain for specific histone marks that integrates multiple copies of transgene expression units individually at genomic regions with highest transcriptional activity. As a result, it achieves exceptionally high protein expression and maximum stability in clone pools and clones, reducing time and manual lab work for selecting superior clones for best titers, proven stability and product quality.